Jyong Biotech Ltd. Ordinary Shares
MENSNASDAQHealthcareBiotechnology
Previous close
$2.18
+$0.02 · +0.93%
MENS company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
26
Expensive
Momentum
31
Weakening
Sentiment
52
Mixed
Risk resilience
17
Extreme Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteJyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- TW
- CEO
- Fu-Feng Kuo
- Listed since
- Jun 17, 2025
- Employees
- 27
Market position
Day range
Current $2.18
52-week range
Current $2.18
- Open
- $2.1456
- Previous close
- $2.16
- Volume
- 17.38K
- 0.21× average
- Average volume
- 83.06K
- Average daily volume
- Market cap
- 165.74M USD
- Beta
- 2.29
- Market reference 1
- 50-day average
- $2.0847
- +4.57% above average
- 200-day average
- $6.7286
- -67.60% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 305.76M USD
- P/E (TTM)
- -25.2×
- P/B (TTM)
- -6.5×
- P/S (TTM)
- 0×
- EV / EBITDA
- -121.96×
- Earnings yield
- -1.62%
- Free cash flow yield
- -1.05%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- 18.75%
- Return on assets
- -22.48%
- Return on invested capital
- 45.99%
Financial health
- Debt / equity
- -0.74×
- Current ratio
- 0.45×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 100K USD | 120K USD | 127K USD | 122K USD | 121K USD |
| Gross profit | −100K USD | −120K USD | −127K USD | −122K USD | −121K USD |
| Research and development | 731K USD | 927K USD | 1.07M USD | 1.29M USD | 1.56M USD |
| Selling, general, and administrative | 1.78M USD | 1.13M USD | 1.73M USD | 1.54M USD | 845K USD |
| Operating expenses | 2.51M USD | 2.06M USD | 2.8M USD | 2.83M USD | 2.4M USD |
| Interest income | 610K USD | 7K USD | 56K USD | 5K USD | 6K USD |
| Interest expense | 2.54M USD | 1.04M USD | 757K USD | 765K USD | 835K USD |
| Depreciation and amortization | 100K USD | 120K USD | 127K USD | 123K USD | 122K USD |
| Operating income | −2.61M USD | −2.06M USD | −2.8M USD | −2.83M USD | −2.4M USD |
| Net income | −4.67M USD | −3.02M USD | −4.4M USD | −6.63M USD | −4.2M USD |
Company facts updated Aug 24, 2026.
MENS news
MENS peers
ETFs holding MENS
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB- Market value
- 466.47K
- Weight
- 0.00%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Fidelity Nasdaq Composite Index ETFONEQ- Market value
- 57.74K
- Weight
- —
- AUM
- 10.35B USD
- Expense ratio
- 0.21%
- Price / 1D
- $103.14+0.41%
Invesco Nasdaq Biotechnology ETFIBBQ- Market value
- 9.54K
- Weight
- 0.01%
- AUM
- 94.57M USD
- Expense ratio
- 0.19%
- Price / 1D
- $36.29+1.37%
ProShares Ultra Nasdaq BiotechnologyBIB- Market value
- 5.66K
- Weight
- 0.01%
- AUM
- 103.78M USD
- Expense ratio
- 1.19%
- Price / 1D
- $122.16+2.73%
Continue in GoAI
Research MENSresearch.disclaimer